Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

Abstract

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

1 . A compound of the formula I:  
         Azabicyclo-N(R 1 )—C(═O)—W   Formula I  
       wherein R 1  is H, alkyl, or haloalkyl;  
       Azabicyclo is  
       
         
           
           
               
               
           
         
         R 2  is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;  
         k is 1 or 2, provided that when k is 2, one R 2  is other than H;  
         Each R 3  is independently H, alkyl, or substituted alkyl;  
         R 4  is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, —OH, —CN, —NH 2 , —NH(alkyl), or —N(alkyl) 2 ;  
         W is  
         
           
             
             
                 
                 
             
           
         
         wherein W 1  is N or CH;  
         Each W 2 is N or C(R 5 ), provided that no more than one W 2  is N;  
         Each R 5  is independently H, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , aryl, R 7 , R 9 , or two R 5  on adjacent carbon atoms may combine for W to be a 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, and R 6 ;  
         R 6  is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R, —S(O)R 8 , —OS(O) 2 R 8 , —NR 8 R 8 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)NR 8 R 8 , —NR 8 C(O)R 8 , —S(O) 2 NR 8 R 8 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)NR 8 R 8 , substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R 15 , naphthyl, or naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R 15 ;  
         R 7  is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R 14 )—, and —S—, and having 0-1 substituent selected from R 15 , and further having 0-3 substituents independently selected from F, Cl, Br, or I, wherein the R 7  moiety attaches to other substituents as defined in formula I at any position as valency allows;  
         Each R 8  is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 ;  
         R 9  is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from ═N— and having 0-1 substituent selected from R 15  and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R 9  moiety attaches to other substituents as defined in formula I at any position as valency allows;  
         Each R 10  is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R 13 , cycloalkyl substituted with 1 substituent selected from R 13 , heterocycloalkyl substituted with 1 substituent selected from R 13 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;  
         Each R 11  is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         R 13  is —OR 11 , —SR 11 , —NR 11 R 11 , —C(O)R 11 , —SOR 11 , —SO 2 R 11 , —C(O)NR 11 R 11 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 NR 11 R 11 , —NR 11 S(O) 2 R 11 , or —NO 2 ;  
         R 14  is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;  
         R 15  is alkyl, substituted alkyl, halogenated alkyl, —OR 11 , —CN, —NO 2 , —NR 10 R 10 ;  
         R 16  is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R 15 ; or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.  
       
     
     
         2 . The compound of  claim 1 , wherein R 1  is H, lower alkyl, or cycloalkyl.  
     
     
         3 . The compound of  claim 2 , wherein R 2  is H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.  
     
     
         4 . The compound of  claim 3 , wherein R 2  is H, or lower alkyl.  
     
     
         5 - 15 . (canceled)  
     
     
         16 . The compound of  claim 4 , wherein Azabicyclco is II.  
     
     
         17 . The compound of  claim 16 , wherein W 1  is CH.  
     
     
         18 . The compound of  claim 17 , wherein each R 5  is independently H, lower alkyl, lower substituted alkyl, lower halogenated alkyl, lower alkenyl, lower substituted alkenyl, lower halogenated alkenyl, lower alkynyl, lower substituted alkynyl, lower halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , phenyl, substituted phenyl, R 7 , or R 9 , 
 wherein each R 10  is independently H, lower alkyl, or lower halogenated alkyl, and wherein each R 16  is independently H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.    
     
     
         19 . The compound of  claim 18 , wherein the compound is 
 N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]indolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-methylindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-chloroindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-bromoindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-cyanoindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-ethynylindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-methylindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-chloroindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-bromoindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-cyanoindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-ethynylindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-chloroindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromoindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-cyanoindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-ethynylindolizine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]indolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-methylindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-chloroindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-bromoindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-cyanoindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-l1-ethynylindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-methylindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-chloroindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-bromoindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-cyanoindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-ethynylindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-chloroindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromoindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-cyanoindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-ethynylindolizine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,5-a]pyridine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,5-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,2-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-chloroimidazo[1,2-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-bromoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-cyanoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-ethynylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,2-a]pyridine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-chloroimidazo[1,2-a]pyridine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-bromoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-cyanoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-ethynylimidazo[1,2-a]pyridine-7-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         20 . The compound of  claim 18 , wherein two R 5  on adjacent carbon atoms combine for W to be the 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated alkenyl, lower halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , lower substituted alkyl, lower substituted alkenyl, lower substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, or phenyl optionally substituted with up to 2 substituents independently selected from F, Cl, Br, I and R 15 , 
 wherein each R 8  is independently H, lower alkyl, lower halogenated alkyl, lower substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 .    
     
     
         21 . The compound of  claim 20 , wherein the compound is N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrido[1,2-a]indole-7-carboxamide; 
 N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-9H-carbazole-3-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         22 . The compound of  claim 16 , wherein W 1  is N.  
     
     
         23 . The compound of  claim 22 , wherein each R 5  is independently H, lower alkyl, lower substituted alkyl, lower halogenated alkyl, lower alkenyl, lower substituted alkenyl, lower halogenated alkenyl, lower alkynyl, lower substituted alkynyl, lower halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , phenyl, substituted phenyl, R 7 , or R 9 , 
 wherein each R 10  is independently H, lower alkyl, or lower halogenated alkyl, and wherein each R 16  is independently H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.    
     
     
         24 . The compound of  claim 23 , wherein the compound is 
 N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-prop-1-ynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-(3-hydroxyprop-1-ynyl)pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-8-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-8-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-8-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-8-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-8-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,2-a]pyrazine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,5-a]pyrazine-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-pyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-5-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-5-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-5-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-5-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-5-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-6-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-b  4 S)-1-azabicyclo[2.2.1]hept-3-yl]-7-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-7-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,2-c]pyrimidine-7-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]imidazo[1,5-c]pyrimidine-7-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         25 . The compound of  claim 22 , wherein two R 5  on adjacent carbon atoms combine for W to be the 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated alkenyl, lower halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , lower substituted alkyl, lower substituted alkenyl, lower substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, or phenyl optionally substituted with up to 2 substituents independently selected from F, Cl, Br, I and R 15 , 
 wherein each R 8  is independently H, lower alkyl, lower halogenated alkyl, lower substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 .    
     
     
         26 . The compound of  claim 25 , wherein the compound is 
 N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrazino[1,2-a]indole-3-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-9H-beta-carboline-3-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         27 . The compound of  claim 4 , wherein Azabicyclco is III.  
     
     
         28 . The compound of  claim 27 , wherein k is 1.  
     
     
         29 . The compound of  claim 28 , wherein W 1  is CH.  
     
     
         30 . The compound of  claim 29 , wherein each R 5  is independently H, lower alkyl, lower substituted alkyl, lower halogenated alkyl, lower alkenyl, lower substituted alkenyl, lower halogenated alkenyl, lower alkynyl, lower substituted alkynyl, lower halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , phenyl, substituted phenyl, R 7 , or R 9 , 
 wherein each R 10  is independently H, lower alkyl, or lower halogenated alkyl, and wherein each R 16  is independently H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.    
     
     
         31 . The compound of  claim 30 , wherein the compound is 
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]indolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-methylindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-chloroindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-bromoindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-cyanoindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-ethynylindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-methylindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-chloroindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-bromoindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyanoindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethynylindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-chloroindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-bromoindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-cyanoindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethynylindolizine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]indolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-methylindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-chloroindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-bromoindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-cyanoindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-ethynylindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-methylindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-chloroindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-bromoindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyanoindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethynylindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-chloroindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-bromoindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-cyanoindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethynylindolizine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,5-a]pyridine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,5-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-chloroimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-bromoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyanoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethynylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-chloroimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-bromoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyanoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethynylimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]indolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-methylindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-chloroindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-bromoindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-cyanoindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-ethynylindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-methylindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-chloroindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-bromoindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-cyanoindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-ethynylindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-methylindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-chloroindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-bromoindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-cyanoindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-ethynylindolizine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]indolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-methylindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-chloroindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-bromoindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-cyanoindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-1-ethynylindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-methylindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-chloroindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-bromoindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-cyanoindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-ethynylindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-methylindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-chloroindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-bromoindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-cyanoindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-3-ethynylindolizine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,5-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,5-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-chloroimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-bromoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-cyanoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-ethynylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-chloroimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-bromoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-cyanoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-2-ethynylimidazo[1,2-a]pyridine-7-carboxamide;    pharmaceutically acceptable salt thereof.    
     
     
         32 . The compound of  claim 29 , wherein two R 5  on adjacent carbon atoms combine for W to be the 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated alkenyl, lower halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , lower substituted alkyl, lower substituted alkenyl, lower substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, or phenyl optionally substituted with up to 2 substituents independently selected from F, Cl, Br, I and R 15 , 
 wherein each R 8  is independently H, lower alkyl, lower halogenated alkyl, lower substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 .    
     
     
         33 . The compound of  claim 32 , wherein the compound is 
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrido[1,2-a]indole-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-9H-carbazole-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]pyrido[1,2-a]indole-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-9H-carbazole-3-carboxamide; or pharmaceutically acceptable salt thereof.    
     
     
         34 . The compound of  claim 28 , wherein W 1  is N.  
     
     
         35 . The compound of  claim 34 , wherein each R 5  is independently H, lower alkyl, lower substituted alkyl, lower halogenated alkyl, lower alkenyl, lower substituted alkenyl, lower halogenated alkenyl, lower alkynyl, lower substituted alkynyl, lower halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , phenyl, substituted phenyl, R 7 , or R 9 , 
 wherein each R 10  is independently H, lower alkyl, or lower halogenated alkyl, and wherein each R 16  is independently H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.    
     
     
         36 . The compound of  claim 25 , wherein the compound is 
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-prop-1-ynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-(3-hydroxyprop-1-ynyl)pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-8-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-8-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-8-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-8-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-8-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl] imidazo[1,2-a]pyrazine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,5-a]pyrazine-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-pyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-5-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-5-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-5-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-5-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-5-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-6-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-7-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,2-c]pyrimidine-7-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]imidazo[1,5-c]pyrimidine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-prop-1-ynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-(3-hydroxyprop-1-ynyl)pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-8-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-8-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-8-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-8-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-8-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,2-a]pyrazine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,5-a]pyrazine-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-pyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-5-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-5-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-5-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-5-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-5-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-6-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-chloropyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-7-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,2-c]pyrimidine-7-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]imidazo[1,5-c]pyrimidine-7-carboxamide; or    pharmaceutically acceptable salt thereof.    
     
     
         37 . The compound of  claim 34 , wherein two R 5  on adjacent carbon atoms combine for W to be the 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated alkenyl, lower halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , lower substituted alkyl, lower substituted alkenyl, lower substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, or phenyl optionally substituted with up to 2 substituents independently selected from F, Cl, Br, I and R 15 , 
 wherein each R 8  is independently H, lower alkyl, lower halogenated alkyl, lower substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 .    
     
     
         38 . The compound of  claim 37 , wherein the compound is 
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-9H-beta-carboline-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]pyrazino[1,2-a]indole-3-carboxamide;    N-[(3R)-1-azabicyclo[3.2.1]non-3-yl]-9H-beta-carboline-3-carboxamide; or    pharmaceutically acceptable salt thereof.    
     
     
         39 - 49 . (canceled)  
     
     
         50 . The compound of  claim 4 , wherein Azabicyclo is VII.  
     
     
         51 . The compound of  claim 50 , wherein each R 3  is independently H, lower alkyl, or lower substituted alkyl.  
     
     
         52 . The compound of  claim 51 , wherein R 4  is H, lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, —OH, —CN, —NH 2 , 
 —NH(lower alkyl), or —N(lower alkyl) 2 .    
     
     
         53 . The compound of  claim 52 , wherein R 4  is an amino protecting group.  
     
     
         54 . The compound of  claim 52 , wherein each R 3 , and R 4  are H.  
     
     
         55 . The compound of  claim 54 , wherein W 1  is CH.  
     
     
         56 . The compound of  claim 55 , wherein each R 5  is independently H, lower alkyl, lower substituted alkyl, lower halogenated alkyl, lower alkenyl, lower substituted alkenyl, lower halogenated alkenyl, lower alkynyl, lower substituted alkynyl, lower halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , phenyl, substituted phenyl, R 7 , or R 9 , 
 wherein each R 10  is independently H, lower alkyl, or lower halogenated alkyl, and wherein each R 16  is independently H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.    
     
     
         57 . The compound of  claim 56 , wherein the compound is 
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]indolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-methylindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-chloroindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-bromoindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-cyanoindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-ethynylindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methylindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloroindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromoindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanoindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chloroindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromoindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanoindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylindolizine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]indolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-methylindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-chloroindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-bromoindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-cyanoindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-ethynylindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methylindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloroindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromoindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanoindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chloroindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromoindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanoindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylindolizine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,5-a]pyridine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,5-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,2-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloroimidazo[1,2-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanoimidazo[1,2-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylimidazo[1,2-a]pyridine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,2-a]pyridine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloroimidazo[1,2-a]pyridine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanoimidazo[1,2-a]pyridine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylimidazo[1,2-a]pyridine-7-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         58 . The compound of  claim 55 , wherein two R 5  on adjacent carbon atoms combine for W to be the 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated alkenyl, lower halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , lower substituted alkyl, lower substituted alkenyl, lower substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, or phenyl optionally substituted with up to 2 substituents independently selected from F, Cl, Br, I and R 15 , 
 wherein each R 8  is independently H, lower alkyl, lower halogenated alkyl, lower substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 .    
     
     
         59 . The compound of  claim 58 , wherein the compound is 
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrido[1,2-a]indole-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-9H-carbazole-3-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         60 . The compound of  claim 54 , wherein W 1  is N.  
     
     
         61 . The compound of  claim 60 , wherein each R 5  is independently H, lower alkyl, lower substituted alkyl, lower halogenated alkyl, lower alkenyl, lower substituted alkenyl, lower halogenated alkenyl, lower alkynyl, lower substituted alkynyl, lower halogenated alkynyl, —CN, —NO 2 , F, Br, Cl, I, —OR 16 , —C(O)N(R 10 ) 2 , —N(R 10 ) 2 , —SR 16 , —S(O) 2 R 16 , —C(O)R 16 , —CO 2 R 16 , phenyl, substituted phenyl, R 7 , or R 9 , 
 wherein each R 10  is independently H, lower alkyl, or lower halogenated alkyl, and wherein each R 16  is independently H, lower alkyl, lower halogenated alkyl, or lower substituted alkyl.    
     
     
         62 . The compound of  claim 61 , wherein the compound is 
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-prop-1-ynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-(3-hydroxyprop-1-ynyl)pyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-8-cyanopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-8-methylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-8-chloropyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-8-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-8-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,2-a]pyrazine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,5-a]pyrazine-6-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-pyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-5-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-5-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-5-chloropyrrolo[1,2-c]pyrimidin-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-5-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-5-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloropyrrolo[1,2-c]pyrimidin-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-bromopyrrolo[1,2-c]pyrimidin-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-ethynylpyrrolo[1,2-c]pyrimidin-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-cyanopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-methylpyrrolo[1,2-c]pyrimidin-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-chloropyrrolo[1,2-c]pyrimidin-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-bromopyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-7-ethynylpyrrolo[1,2-c]pyrimidine-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,2-c]pyrimidine-7-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]imidazo[1,5-c]pyrimidine-7-carboxamide;    
     
     
         63 . The compound of  claim 60 , wherein two R 5  on adjacent carbon atoms combine for W to be the 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with up to 2 substitutents independently selected from F, Cl, Br, I, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated alkenyl, lower halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , lower substituted alkyl, lower substituted alkenyl, lower substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, or phenyl optionally substituted with up to 2 substituents independently selected from F, Cl, Br, I and R 15 , 
 wherein each R 8  is independently H, lower alkyl, lower halogenated alkyl, lower substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 .    
     
     
         64 . The compound of  claim 63 , wherein the compound is 
 N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrazino(1,2-a]indole-3-carboxamide;    N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-9H-beta-carboline-3-carboxamide;    or pharmaceutically acceptable salt thereof.    
     
     
         65 . A pharmaceutical composition comprising a compound according to  claim 1 , anti-psychotic agent(s), and a pharmaceutically acceptable excipient.  
     
     
         66 . The pharmaceutical composition according to  claim 65 , wherein said compound and said agent are to be independently administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.  
     
     
         67 . The pharmaceutical composition according to  claim 66 , wherein said compound is administered in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day.  
     
     
         68 . The pharmaceutical composition according to  claim 66 , wherein said compound is administered in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.  
     
     
         69 . The pharmaceutical composition according to  claim 65 , comprising a compound according to  claim 1  and a pharmaceutically acceptable excipient.  
     
     
         70 . The pharmaceutical composition according to  claim 69 , wherein said compound is administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.  
     
     
         71 . The pharmaceutical composition according to  claim 70 , wherein said compound is administered in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day.  
     
     
         72 . The pharmaceutical composition according to  claim 70 , wherein said compound is administered in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.  
     
     
         73 . A method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of an α7 nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         74 . The method according to  claim 73 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.  
     
     
         75 . The method according to  claim 73 , wherein the disease or condition is schizophrenia or psychosis.  
     
     
         76 . The method of  claim 75 , wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist and an anti-psychotic agent for a therapeutically effective interval.  
     
     
         77 . The method according to  claim 73 , wherein the disease or condition is depression, or anxiety and general anxiety disorders and post traumatic stress disorder.  
     
     
         78 . The method according to  claim 73 , wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.  
     
     
         79 . The method according to  claim 73 , wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.